FDA Panel Backs Peptide Injections Despite Scientists' Safety Warnings

A Wellness Trend Gets a Government Hearing

More than a half-dozen peptides — unproven substances that have become a growing wellness trend despite little evidence they are safe or effective — came before federal health advisers this week. The two-day review, which concluded Friday, July 25, put a spotlight on a booming underground market that has largely operated in the shadows of mainstream medicine, fueled by social media hype and celebrity endorsements.

The meeting, hosted by the Food and Drug Administration, had the backing of Health Secretary Robert F. Kennedy Jr., who has described himself as a "big fan" of peptides and vowed to overturn industry restrictions put in place under President Joe Biden. Peptide supporters include podcaster Joe Rogan and wellness influencers such as Gary Brecka, a supporter of Kennedy's "Make America Healthy Again" agenda who sells peptide vials online, while social media platforms are brimming with testimonials from people claiming the substances helped them build muscle, recover from injuries, or look younger.

What the Panel Actually Voted On

The FDA's Pharmacy Compounding Advisory Committee met on July 23 and July 24 at the agency's White Oak campus in Silver Spring, Maryland, to review seven bulk drug substances that pharmacies have compounded into injectable, nasal spray, oral, and topical products for years — without any of them ever appearing on the FDA's official list of approved substances. On Thursday, the committee voted in favor of four peptides: BPC-157, KPV, TB-500, and MOTS-c.

The committee's votes do not make the peptides FDA-approved drugs. Instead, they are recommending that the peptides be added to a list of drugs that compounding pharmacies are allowed to make — with the final decision coming from the FDA in the form of a rule proposal. Committee members who voted yes generally believed the risks to be minimal, while those who voted no worried about safety risks and effectiveness, and expressed concern that adding the peptides to the compounding list would create a false impression that they had been evaluated with the same rigorous standards as an FDA-approved drug.

Scientists Say the Evidence Isn't There

Again and again, regulators said they could find little data on safety or effectiveness and raised concerns about risks of contamination, allergic reactions, and quality control — and most of the data they did find came from studies in animals, not humans. The FDA's own scientists raised a more fundamental problem: it's unclear, chemically, what these peptides even are, with no universally accepted chemical formula for each substance, making it extremely difficult for the FDA to evaluate their use.

BPC-157, evaluated for ulcerative colitis, drew FDA attention over adverse event reports tied to compounded injectable products, including a patient who developed shortness of breath and another who developed diffuse hyperpigmentation after using a blended BPC-157/TB-500 product labeled "research purposes only." Other substance-specific flags included epitalon's telomerase activation with uncertain carcinogenicity, Semax anticoagulant and amphetamine-potentiation signals, and WADA-prohibited status for MOTS-c and TB-500.

Conflicts of Interest Cloud the Process

The panel of outside advisers included at least seven doctors or pharmacists with financial ties to the peptide industry — among them owners of wellness clinics that sell peptides, pharmacies that produce the formulas, and online consulting businesses that promote them. Eight panel members were appointed under Kennedy, including six who run clinics that offer peptides, and one committee member is the son of a congresswoman who had previously written to Kennedy asking that compounders be allowed to make certain peptides.

One critic told reporters that "what I think we're seeing is the demise of the advisory committee as a useful instrument in scientific decision-making under this administration," adding that the committee was "stacked" with people who "voted in favor of these products anyway" despite "extremely weak evidence." Even a telehealth company representative whose firm stood to benefit commercially from the outcome acknowledged the limits of the science: "I'm not going to tell you that the evidence for BPC-157 is strong. It isn't, and I won't overclaim," said the chief medical officer of the online medication provider's "Hims" branch. With the FDA still holding final authority over any rule change, the real battle over peptide access — and accountability — is just beginning.